Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer

Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (Single Technology Assessment)

As part of the NICE single technology appraisal process, the Aberdeen evidence review group (ERG) was invited to critically review the company’s submission related to the clinical and cost-effectiveness of Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer. The appraisal is ongoing and NICE are expected to publish guidance in 2020: Lorlatinib for treating ALK-positive advanced non-small-cell lung cancer [ID1338] In development [GID-TA10317]

HERU researchers involved in this research project:  Graham Scotland and Daniel Kopasker

External collaborators: Ramsay, C., Brazzelli, M., Cummins, E. and Campbell, M. (Health Services Research Unit (HSRU), University of Aberdeen).

Publications

Robertson, C., Fielding, S., Walker, A., Kopasker, D., Vadiveloo, T., Manson, P., Price, G., Brazelli, M. and Scotland, G. (2019) Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer, (NICE Technology Appraisal Guidance - GID-TA10317), Aberdeen Health Technology Assessment Group.